IMNM
Immunome, Inc.
Biotechnology · Healthcare · United States
18.21
close · 2026-10-30
value
48
cheaper than peers48
quality
46
stronger fundamentals46
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | -0.4% | 81 |
| cash flow yield, 3 years ago | -1.3% | 80 |
| cash flow yield, 1 year ago | -7.6% | 57 |
| cash flow yield, latest year | -9.6% | 51 |
| earnings yield, latest year | -13.3% | 48 |
| earnings yield, 3 years ago | -17.0% | 47 |
| price to book | 3.93× | 42 |
| earnings yield, 2 years ago | -29.5% | 39 |
| earnings yield, 1 year ago | -27.5% | 39 |
| price to sales | 535.20× | 6 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.6% | 96 |
| return on equity | -50.1% | 47 |
| operating margin | -5698.8% | 3 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$139.3M |
| employees | 206 |
| first trade | 2020-10-02 |
| next earnings | not reported |
| fundamentals updated | 2026-07-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.43 | -5.00 | -5.38 | -3.09 |
| free cash flow | -$206.8M | -$164.3M | -$8.4M | -$28.9M |
| net income | -$212.4M | -$293.0M | -$106.8M | -$36.9M |
| revenue | $6.9M | $9.0M | $14.0M | $0 |
| unusual items | not reported | -$152.3M | -$80.8M | $0 |